Home > News > Pharmos Completes Phase 1 Study
November 14th, 2006
Pharmos Completes Phase 1 Study
Abstract:
Pharmos Corporation (Nasdaq: PARS - News) announced today it has completed its initial analysis of data from a recently completed Phase 1 study of its proprietary NanoEmulsion topical drug delivery technology formulated with diclofenac.
Source:
Yahoo
Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||